Loading...
Market
How many new VTE treatment products will Stryker launch by end of 2025 post-acquisition?
2
Resolution / Starting Odds
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Product announcements and releases by Stryker
Story
Stryker to Acquire Inari Medical for $4.9 Billion at $80/Share, Focusing on VTE Treatments
Jan 6, 2025, 09:09 PM
Stryker Corp. has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, valuing the deal at approximately $4.9 billion. This acquisition will allow Stryker to expand its offerings into the high-growth peripheral vascular segment, focusing on venous thromboembolism (VTE) treatments. Inari's innovative product portfolio, which includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism, complements Stryker's existing Neurovascular business. The transaction is expected to close by the end of the first quarter of 2025, pending customary closing conditions including regulatory approvals.
View original story
Similar markets
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
Completed • 25%
Delayed • 25%
Cancelled • 25%
Modified Terms • 25%
Full Integration • 25%
Discontinued Products • 25%
Independent Operation • 25%
Partial Integration • 25%
1 major competitor • 25%
No major competitors • 25%
2 major competitors • 25%
3 or more major competitors • 25%
Yes • 50%
No • 50%
No international approvals • 25%
1 to 2 international approvals • 25%
3 to 4 international approvals • 25%
5 or more international approvals • 25%
$100 million to $200 million • 25%
More than $200 million • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
Positive • 25%
Unchanged • 25%
Negative • 25%
Neutral • 25%
Less than 10% • 25%
More than 50% • 25%
26% to 50% • 25%
10% to 25% • 25%
No • 50%
Yes • 50%